Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter Sells 1,000 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $380.99, for a total transaction of $380,990.00. Following the sale, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Axon Enterprise Stock Down 0.8 %

Axon Enterprise stock opened at $382.57 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company’s 50-day moving average is $340.58 and its 200-day moving average is $315.24. The firm has a market capitalization of $28.87 billion, a PE ratio of 111.86, a P/E/G ratio of 10.30 and a beta of 0.94. Axon Enterprise, Inc. has a fifty-two week low of $189.12 and a fifty-two week high of $386.54.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s revenue was up 34.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.80 earnings per share. Sell-side analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Institutional Trading of Axon Enterprise

Several institutional investors have recently added to or reduced their stakes in AXON. Dorsey Wright & Associates raised its holdings in Axon Enterprise by 0.3% in the 2nd quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after acquiring an additional 39 shares in the last quarter. Avantax Advisory Services Inc. raised its position in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after acquiring an additional 40 shares during the last quarter. Brookstone Capital Management raised its holdings in Axon Enterprise by 5.1% during the 1st quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 41 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in Axon Enterprise by 1.1% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock worth $1,033,000 after buying an additional 43 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of Axon Enterprise by 1.5% in the 2nd quarter. CWM LLC now owns 2,820 shares of the biotechnology company’s stock valued at $830,000 after purchasing an additional 43 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on AXON shares. Craig Hallum lifted their target price on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. JMP Securities boosted their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC restated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective for the company. Finally, Robert W. Baird lifted their target price on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.